

SOGUG

Annual Report

2022



SOGUG
INVESTIGAR · APRENDER · DIVULGAR · CURAR

Dear Members,

It is time to take stock of our first year in our path as the Board of Directors of SOGUG, thanks to the trust you have placed on us and that we have assumed with all the necessary responsibility and drive to keep moving forward toward growing and consolidating the group as a leader in genitourinary oncology in Spain.

SOGUG is a group open to all oncologists involved in the treatment of genitourinary tumours and to collaborations with any specialists who wish to align themselves with the group's objectives. At the end of 2022, we had 553 members, and we keep growing.

Our commitment to work with multi-disciplinary teams in the field of genitourinary tumours is strong, since we believe that we all contribute and add something from our best knowledge and experience. In this sense, we have developed the I2GU project in urothelial cancer, with the participation of other specialists (urologists, radiation oncologists, nuclear medicine physicians, radiologists, pathologists and chemists), which has been highly beneficial and has led to the publication of four consensus review articles, two of which have been published this year in high-impact journals. In line with this, we have started the ENFOCA2 Project in prostate cancer, which will also involve other renowned specialists in the genitourinary field and will consider the perspective of patients with this disease.

In the field of research, SOGUG has a very strong infrastructure for the development of clinical trials, with excellent professionals in the Research Support Office and advisory and financial control teams for the proper management of the necessary resources to support this infrastructure that the group has made available to partners. SOGUG has a long research tradition, having sponsored many clinical trials in collaboration with external

sponsors and other international cooperative groups (e.g., GETUG, SAKK, etc.), and nearly 6,000 patients from over 50 Spanish centres have participated in SOGUG clinical trials.

Regarding education, aside from stable training events (annual training courses, post-congress conferences, and the annual Scientific Symposium), this year we have developed new projects, of which we would like to highlight PROFIT (from its Spanish initials, *Programa Formativo de Investigación Traslacional en Oncología Genitourinaria*, or Translational research in genitourinary oncology training programme), to train clinical oncologists in the key aspects of basic and translational research in the field of genitourinary tumours and provide them with essential knowledge about the molecular characteristics that are at the basis of precision oncology. This year, we have held the first SYNERGY meeting with Portuguese oncologists, where we discussed the state of the skill in urothelial cancer.

We have many activities that focus on patients with genitourinary tumours: throughout this year, we have taken the 50/50 Project to different autonomous communities again, and we are still committed to the Expert Patient Project in different GU tumours.

In the field of Communication, SOGUG is working to increase its presence in social and other media. In 2022, the group established an institutional collaboration agreement with the Prostate Cancer Foundation and its subsidiary UroToday, which has translated into the first media coverage of the Scientific Symposium with active participation of its CEO, Dr. Charles Ryan, in an associated event with prostate cancer patients that took place during the Symposium. This agreement is meant to give

Table of Contents

a wider dissemination of SOGUG events at an international level, particularly in Latin America.

We keep working every day so that all of you, without exception, can have access to trainings and researches, and can participate in all the activities sponsored by the group.

Lastly, we would like to commend our staff for the work carried out and their professionalism, thank the rest of the Board of Directors for their dedication and effort, and the collaborating companies for their invaluable and necessary assistance to carry out the group's activities.

We will keep trying to improve communication with all of you, as well as integrate you in the group's different activities. We are open to your suggestions and feedback, so do not hesitate to share them with us through the communication channels, and we encourage you to complete the annual critical assessment survey of the group's activities.

Warm regards,

Aránzazu González del Alba
Cristina Suárez
Begoña Pérez-Valderrama

1	About SOGUG	4
2	Organisation Board of Directors Team of SOGUG professionals General organisation	7
3	Members	13
4	Rules and Procedures Rules for the development of SOGUG projects Workflow Search engine	29
5	Activity Own projects Projects in collaboration with SOGUG Projects supported by SOGUG Education Scientific activity Summary of activities by committee	41
6	The SOGUG Foundation The SOGUG Foundation Activities of the Foundation	61
7	Financial Balance 2022 Revenue 2022 Expenses 2008-2022 Turnover	67

About SOGUG



About SOGUG

Mission · Our Reason of Being

Promote the development of research and continuing education programmes in the field of urological tumours.

Provide information and support to patients with these pathologies and raise awareness among the population in general.

Vision

Be the benchmark non-profit association at the national level that cares and develops programmes and standards for the treatment of genitourinary tumours, and looks after the well-being of society and patients.

Values

Scientific and research excellence.

The team as a source of strength.

Commitment with patients, relatives and society.

Integrity.

Renovation through education.

SOGUG is a non-profit cooperative group founded in 1998. It is dedicated to the treatment and study of genitourinary tumours and has 553 members, mainly from the field of Medical Oncology, but from other specialities as well.

SOGUG's mission is to promote the development of research and continuing education programmes in the field of genitourinary tumours, providing information and support to patients with these pathologies and raising awareness among the population.

The group leads multi-centre trials of all phases in prostate, kidney and bladder tumours, among others, and works intensively in the field of translational research, favouring the interaction between clinical and basic researchers as the backbone to move toward the individualisation of treatments. On the other hand, SOGUG members have a strong commitment with patients, relatives and society. Integrity and renovation are its two other key values. And everything is supported by a pillar made of transparency, rigour and efficacy.

SOGUG has established collaborations with European corporate groups (GETUG, SAKK, MITO), as well as with renowned institutions such as the Spanish National Cancer Research Centre (CNIO) and the universities of Leiden (The Netherlands), Cambridge and Queen Mary University (England), and San Francisco (UCSF, USA). Furthermore, the group is associated with the European Organisation for the Research and Treatment of Cancer (EORTC) through the CAREFOR initiative, and has participated in European consortia within the European Union's Seventh Framework Programme to promote excellence in research (the EuroTARGET project).

Organisation



Board of Directors

November 2021 - November 2024

Representatives

The Board of Directors (BoD) of SOGUG is democratically elected by the vote of its members every 3 years. It is made by:

- A president, a vice president and a secretary, who represent the group and coordinate all activities.
- Eight committee members, who coordinate all activities related with their respective fields.



Aránzazu González del Alba Baamonde, MD

President
Consultant of the Department of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid



Cristina Suárez Rodríguez, MD

Vice President
Consultant of the Department of Medical Oncology, Vall d'Hebron Hospital, Barcelona



Begoña Pérez Valderrama, MD

Secretary
Consultant of the Department of Medical Oncology, Virgen del Rocío University Hospital of Sevilla

Committee members



Ovidio Fernández Calvo, MD

Continuing Education
Consultant of the Department of Medical Oncology, Ourense Hospital Complex. Santa María Nai de Orense Hospital



Enrique Gallardo Díaz, MD

Treasury, the SOGUG Foundation, Interdisciplinary Relationships
Senior Consultant of the Department of Medical Oncology, Parc Taulí de Sabadell Univ. Hospital, Barcelona



Julio Lambea Sorrosal, MD

Clinical and Translational Research
Consultant of the Department of Medical Oncology, Lozano Blesa Clinical Hospital, Zaragoza



Martín Lázaro Quintela, MD

Activities with Patients
Consultant of the Department of Medical Oncology, University Hospital Complex of Vigo



María José Méndez Vidal, MD

Event Coordination, Interdisciplinary Relationships
Consultant of the Department of Medical Oncology, Reina Sofía de Córdoba Hospital



Ignacio Peláez Fernández, MD

Communication and dissemination (web, social media, press)
Consultant of the Department of Medical Oncology, Univ. Hospital of Cabueñes, Gijón



Gustavo Rubio Romero, MD

Continuing Education
Consultant of the Department of Medical Oncology, Reina Sofía University Hospital, San Sebastián de los Reyes, Madrid



Verónica Calderero Aragón, MD

Activities with Patients
Consultant of the Department of Medical Oncology, San Jorge University Hospital, Huesca San Jorge, Huesca

Team of SOGUG Professionals

SOGUG has its own team of professionals, whose work is essential to face the increasing number of projects in development. The staff of SOGUG provides the Board of Directors with managerial assistance according to the following responsibilities:

Management SOGUG

Representation and negotiation on behalf of the Board of Directors, and execution of its agreements.



Natalia Bellido de Lestable

Administrative and Managing Office

Safekeeping of documents, members directory, institutional relations, and communication.



Silvia Martínez Cruz



Almudena Garzón Ruiz

Research Office

Collaboration with the design, development, execution and follow-up of SOGUG research projects.



Isabel Grau Miró



Macarena Cruz Navas

Furthermore, SOGUG has external management of its financial activities since 2018:

Financial and Legal Team

Account control, tax obligations, and financial follow-up of projects and contracts.

Herraiz & Partners Consultants

Law firm specialized in labour, tax, and commercial management in the field of research.

CIDI Salud

Company dedicated to strategic and operations consultancy, specialized in the health sector.


Goldwyns

Auditing company.

DS&C

Compliance project with the European Regulation on the protection of personal data (GDPR).

General Organisation



Members



Members

553

SOGUG keeps growing, now with 553 members, of which

439

are full members.

114

are supporting members.

8

new membership requests received in the last fiscal year.

Communication with members will be performed through different channels. During 2022, 102 communications have been sent by email by the Secretary to inform about different aspects of interest for members, highlighting the following topics:

- **Information about SOGUG:** Campaigns containing useful news for members, such as the start of in-person and online courses, as well as other activities from our partners, monthly updates of projects such as Must Read, quarterly updates of SOGUG *Contigo* project, initiatives with patients, job offers, SOGUG Info's monthly newsletter, etc.
- **Dissemination to members** of events associated with genitourinary oncology or of general interest.
- **Surveys** requesting members' active participation.
- **Announcements:** Group meetings, organisation of courses and symposiums, etc.
- **Clinical Studies:** Communication of the start of clinical trials requesting the participation of members and updates.

On the other hand, queries made to the Secretary have remained the same as in 2021, with around 900 queries made by phone or email regarding online courses, the website, membership applications, support, certificate requests, incidences, etc.


Based on the new General Data Protection Regulation, the Organic Law on Data Protection and Guarantee of Digital Rights, and the agreed improvement plan, SOGUG has performed several actions to comply with the principle of proactive responsibility and annually check that proper technical and organisational measures have been taken to ensure the rights of the people involved. In this sense, several contracts in which SOGUG was the sponsor of a study have been audited by sampling to check their compliance with rules and procedures.



Satisfaction Survey

In the last quarter of 2022, all SOGUG members were sent a survey to measure the degree of overall satisfaction and establish an improvement plan to answer their concerns.

The overall degree of satisfaction was 8.54 over 10. The answers to the different topics set out are shown in the charts below.



● Yes 92.3% ● No 7.7%

Q1. Do you think that belonging to SOGUG contributes something additional to your professional career?


Most popular answers:

- It provides updates about the genitourinary pathology.
- Possibility to participate in researches.
- Possibility to better my education, be up-to-date, and participate in research projects in GU.
- Participate in clinical trials, get oncological information, be in touch with colleagues.
- Possibility to research, learn and do team networking in the field of GU tumours.
- Knowledge, relationships with my colleagues, opportunities to participate in projects, and support by the group with institutional issues.
- SOGUG is doing a magnificent job and that is reflected in the knowledge we can apply in our consults.
- Being part of SOGUG provides me with access to updated medical information.
- The group improves its members' education, facilitates access to trials and supports research.
- Possibility to participate in clinical research, updates, support to new funding.
- Knowledge, updates, and a national network of colleagues to discuss doubts.

Satisfaction Survey


If you answered "No," please, specify:

- More focused on networking and meetings than on clinical trials.



● Yes 89.7% ● No 10.3%


Q2. Do you feel identified with the activities and philosophy of the group?




● Yes 89.7% ● No 7.7% ● Don't know/No answer 2.6%

Q3. Do you consider you have enough information regarding the activities carried out by the group?

Satisfaction Survey




Q4. Did you know that SOGUG has...? Check all that apply.



Q5. Do you know the search engine of SOGUG projects?


Satisfaction Survey



If you answered "No," please, specify:

- I just want to say that I wish all hospitals that showed an interest were able to participate in the clinical trials.
- Medium-sized hospitals have less opportunities. It makes sense to participate in some projects.
- Not all projects are offered to all members.
- Always the same people are invited.

Q6. Regarding SOGUG projects, do you think that all the members of the group are invited to participate?




If you answered "No," please, specify:

- I have not tried it because I don't know where to start.


Q7. When submitting a project for assessment, do you think the procedure was accessible?

Satisfaction Survey




● Yes 61.5% ● No 20.5% ● Don't know/No answer 18%

Q8. Would you like to participate more actively within the group?



Q9. If you answered "Yes" to Q8, in what area(s)?

Satisfaction Survey




● Yes 12.8% ● No 71.8% ● Don't know/No answer 15.4%

Q10. Do you miss any activity not currently promoted by the group?


If you answered "Yes," please, specify:

- A steady grant programme.
- Developed clinical cases that can be used as examples for house officers training.
- Writing Spanish protocols so that all oncologists can unite against the intrusion of other specialities, including efficiency criteria. In prostate cancer, patients' treatment relies on the pharmaceutical industry instead of the decision being based on what's best for each patient. SOGUG must also struggle with the Ministry of Health to protect the speciality against intrusions; otherwise, Uro-oncology will fall in the hands of young urologists and SOGUG will end up disappearing.
- More work is needed to attract clinical trials.



● Daily 0% ● Several times a week 0% ● Several times a month 61.5% ● A few times a year 35.9% ● Never 2.6%


Q11. How often do you visit the website SOGUG.es?



● Yes 82% ● No 2.6% ● Don't know/No answer 15.4%

Q12. Do you think that the design and contents are appropriate?

Satisfaction Survey




● Yes 84.6% ● No 12.8% ● Don't know/No answer 2.6%

If you answered "No," please, specify:

- Many similar presentations to those of the pharmaceutical industry.
- Always the same speakers, especially from the Board of Directors.
- It would be best for me if it started on Thursdays, that way I would only miss two days of work.


Q13. Regarding the SOGUG Symposium, are you satisfied with its design and contents?



● Virtual 2.5% ● In person 38.5% ● Hybrid 59%

Q14. What format would you prefer for the SOGUG Symposium?

Satisfaction Survey




● Yes 87.2% ● No 5.1% ● Don't know/No answer 7.7%

If you answered "No," please, specify:

- Always the same speakers, especially from the Board of Directors.


Q15. Regarding SOGUG courses, are you satisfied with their design and contents?



● Virtual 12.8% ● In person 30.8% ● Hybrid 56.4%

Q16. What format would you prefer for SOGUG courses?

Satisfaction Survey




If you answered "No," please, specify:

- Always the same speakers, especially from the Board of Directors.

● Yes 87.2% ● No 5.1% ● Don't know/No answer 7.7%


Q17. Regarding SOGUG Review Conferences, are you satisfied with their design and contents?



● Virtual 17.9% ● In person 17.9% ● Hybrid 64.2%

Q18. What format would you prefer for SOGUG conferences?

Satisfaction Survey




If you answered "No," please, specify:

- Always the same speakers, especially from the Board of Directors.


● Yes 71.8% ● No 10.3% ● Don't know/No answer 17.9%

Q19. Do you consider that e-learnings for the different GU pathologies are useful for your work?



● Yes 79.4% ● No 10.3% ● I don't know the project 10.3%

Q20. Do you consider that the Must Read project is useful for your work?




● Yes 64.1% ● No 7.7% ● I don't know the project 28.2%


Q21. Do you consider that the PROFIT project is useful for your work?

Satisfaction Survey

Answers (%)



Q21. Mark all the SOGUG projects for patients that you know.



● Yes 89.7% ● No 10.3%

Q22. Overall, are you satisfied with the services you have received from the group in the last year?

Satisfaction Survey

8.41

Q23. Indicate your degree of satisfaction with the way that the SOGUG team processes your documents and handles your doubts, concerns, complaints, etc.

0-10, where 0 = "Not satisfied at all" and 10 = "Very satisfied."

Q26. Feedback and suggestions.

- Facilitate the attendance of registrars. Lately, it is hard to get funding by the pharmaceutical industry for registrars.
- Congratulations! Keep it up!

8.21

Q24. Assess the degree of external visibility of the group.

0-10, where 0 = "Not visible at all" and 10 = "Highest degree of visibility."


8.54

Q25. Please, score your overall degree of satisfaction with the group.

0-10, where 0 = "Not satisfied at all" and 10 = "Very satisfied."

Rules and Procedures





Rules and Procedures for the Development of Projects

In 2016, a project assessment and development protocol was created, which was communicated to all members on the first newsletter of April 2016 (available at www.sogug.es). This protocol has remained in effect and unchanged during 2022. Something new that we added in 2021 was the inclusion of a **Project Application Form** on the website, located in the Area of Professionals, so members can submit their proposals. [Fig. 1]

PROJECT APPLICATION FORM Fig. 1

APPLICANTS INFORMATION

Applicants

TYPE OF PROJECT

SOGUG project Project in collaboration with SOGUG

If it is a collaboration project, indicate the sponsor

PROJECT INFORMATION

Scientific/CT Training/educational
 Patients Other

Title

Description

Objective

Estimated budget

Estimated number of centres/members that will potentially benefit from it

Other comments

Rules for the development of SOGUG projects

New project proposal

Any idea or proposal that is aligned with the objectives and strategic plan of SOGUG may be considered for development by the group. This idea will be initially assessed by the president, the vice president and the secretary, who will check the idea is aligned with the interests and objectives of the group and, if it is, instructions will be provided to be discussed by the Board of Directors, it will be assigned a code, and the development process described below will begin. No project will be considered as belonging to the group if it does not follow the steps indicated herein. This includes not only research studies, but also any initiative, event or activity characteristic of the group or in collaboration with other entities, including conferences and events.

“Project in preparation”, types of projects, and code assignment

All ideas or proposals must be assessed by the BoD. After verifying that the project is aligned with the group's objectives, it will be qualified as **"PROJECT IN PREPARATION."** Based on the degree of involvement of SOGUG in the project, this will be in turn classified into one of three **TYPES OF PROJECTS:**

- **SOGUG Project:** SOGUG is the owner or sponsor. Therefore, we have the highest responsibility for its design, funding, execution, subcontracting, and rights of authorship, publication and marketing, including patents, if any.
- **SOGUG Collaboration Project:** Aligned with SOGUG objectives, but not of our ownership. We just collaborate by contributing a service specified in a contract.
- **Project Supported by SOGUG:** Aligned with SOGUG goals, but we are not the owners or collaborators.

Furthermore, all SOGUG projects will be identified with a code assigned by the secretary, according to the following key [Fig. 2]:

PROJECT IDENTIFICATION CODE

Fig. 2

SOGUG - YEAR - TYPE (subtype) - ORDER NO.

1. SOGUG	All projects will start with "SOGUG."
2. Year	Year of entry of the project in the BoD.
3. Type of Project	Identified by three letters referring to the type of project, plus three additional letters (between brackets) in case there are subtypes:
INF	Infrastructure
CET	Continuing education and training
SYM	Symposium
COU	SOGUG course
ONL	Distance (online) training course
GRN	Grants
OTH	Other
RCT	Research and clinical trials
PRO	Prostate
BLD	Bladder
KDN	Kidney
TRL	Translational research
OTH	Other
PTS	Patients
COL	Collaborations
(F)	Project in collaboration with the SOGUG Foundation

4. Order Number Order number of the "type of project" that year.

Assignment of person(s) responsible and development of the project

When a project has been accepted for development by SOGUG, a person responsible for the project will be immediately assigned, usually the person who had the idea or who will carry out the proposal. A work team will thus be formed made by the person responsible for the project, the committee members of the Board of Directors in charge of the areas involved, and the manager of SOGUG. This team will start working on its design, including the aspects regarding SOPs and the financial report. When projects are directly proposed by the Board of Directors, the Board itself will be responsible for the project. In all cases, the secretary will be in charge of its recording and follow-up, but not of its development.

Those responsible for carrying out the project (the assigned person responsible for the project and committee members) will work on it until its completion, using rigour, transparency, quality and equal opportunity criteria for the participation of the members. All the documents regarding the project will be kept in a project dossier, which, when completed, will be delivered to SOGUG's Secretary in paper or digital format for safekeeping. When it is required to hire services from companies or individuals outside SOGUG, at least two budgets will be requested, which will be included in the dossier. During the preparation phase of the project, no agreement or final commitment of the financial, scientific or organisational type can be reached with any company, SOGUG member or individual regarding any of the aspects of the project (including scientific matters, authorship, intellectual property, patents, assignment of parts of the project, economical items, etc.).

Once the preparation process of the project is completed, the person responsible for the project will fill out a document called **SUMMARY OF THE PROJECT** [Fig. 3], which will be submitted to the Secretary for monitoring and discussion by the Board of Directors.

SUMMARY OF THE PROJECT *Fig. 3*

PROJECT CODE	PERSON RESPONSIBLE	COMMITTEE MEMBERS OF THE BoD	STATUS
TITLE			

DESCRIPTION

Brief description of the project.

- Scientific projects will include the traditional sections of justification, hypothesis, main and secondary objectives, type of design and methodology, as well as potential start dates, intended duration of the study, intended intermediate analyses, times of communication of results (intermediate and final). They will also include work groups, associations or entities with which they are collaborating and their level of involvement.
- The educational events section will include the justification, objectives, target audience for the activities, mode of evaluation of results, certifications, and anything else considered of interest.
- The rest of the activities will describe all those aspects related with justification, development, and implementation that are considered of interest.

OBJECTIVE AND INTEREST OF THE PROJECT

NUMBER OF CENTRES/MEMBERS THAT WILL BENEFIT FROM IT

FINANCIAL STUDY

Description of the BUDGET, potential expenses and incomes, specifying the different options and budgets consulted (additional documentation may be included, if necessary).

Approval and Implementation of the Project

No project can be started or considered a SOGUG Project until its final approval by the Board of Directors. The Board of Directors shall approve those projects that comply with the following requirements:


1. Completion of the SUMMARY OF THE PROJECT.
2. Alignment with the group's objectives and strategic plan.
3. Rigour in the preparation of the project, considering all desirable aspects for proper development.
4. Financial feasibility.
5. Review by the legal team in case it is considered necessary.
6. Dissemination commitment to all members of SOGUG, who will have access to participate in the project based on criteria previously specified and approved by the BoD.

Once approved by the BoD, the project will be developed within the group according to the agreements that have been authorized about the scientific and financial aspects mentioned above.

Based on the degree of involvement of SOGUG, the following contract models have been created:

- Contract model for **SOGUG PROJECTS** (SOGUG is the sponsor): Agreement between SOGUG and other entities for the funding and/or performance of a research project sponsored by SOGUG.
- Contract model for **COLLABORATION PROJECTS** (SOGUG collaborates in someone else's project): Agreement between SOGUG and another entity to establish a collaboration relationship. They are not SOGUG projects, but SOGUG provides them with assistance.
- Contract model for **SOGUG SUPPORT**: Agreement between SOGUG and another entity interested in having SOGUG scientific support.

These data will be used to generate a **PROJECT DATA SHEET** (*Fig. 4*), which will be available for members on the website and will be updated regularly by the Committee of Projects and Quality.



Search Engine

To facilitate access to information, a project search engine was created in 2016 in the group's new website. Besides making it easy to search for projects through different items, all the relevant information about each project has been entered in it, including the project's Data Sheet, which can be accessed through a link, as well as the study protocol in the case of clinical trials.

This search engine is regularly updated. Furthermore, about every 6 months, an email is sent to all members with an updated list of all the group's projects.

The hierarchical organisational chart used to classify all the projects in the website, and that serves as the basis for the search engine programming, is divided in the following levels:

Project Coding Organisational Chart

Level 1:

All projects are classified into one of these **FOUR GROUPS OF PROJECTS**:

1. **SOGUG Projects**
2. **SOGUG COLLABORATION Projects with other entities**
3. **Projects SUPPORTED by SOGUG**
4. **Projects IN COLLABORATION with the SOGUG FOUNDATION**

Level 2:

SOGUG Projects and SOGUG Collaboration Projects with other entities are, in turn, subclassified into one of these **FOUR TYPES OF PROJECTS**:

- A. **INFRASTRUCTURE**
- B. **CONTINUING EDUCATION AND TRAINING**
- C. **RESEARCH AND CLINICAL TRIALS**
- D. **PROJECTS WITH PATIENTS**

Level 3:

The types of projects may have, in turn, **SUBTYPES OF PROJECTS**:

- A. **INFRASTRUCTURE**
- B. **CONTINUING EDUCATION AND TRAINING**
 - a. **SYMPOSIUM**
 - b. **SOGUG COURSES**
 - c. **DISTANCE (ONLINE) TRAINING COURSES**
 - d. **GRANTS**
 - e. **OTHERS**
- C. **RESEARCH AND CLINICAL TRIALS**
 - a. **PROSTATE**
 - b. **BLADDER**
 - c. **KIDNEY**
 - d. **TRANSLATIONAL**
 - e. **OTHERS**
- D. **PROJECTS WITH PATIENTS**

Programming of the Search Engine

The search engine is programmed in such a way that members can perform a search according to any of the following criteria based on the **PROJECT GROUP, TYPE AND SUBTYPE OF PROJECT.**

This programming has been recently simplified to facilitate the search of specific projects. Thus, when a member wants to search for a project, the following menu unfolds, allowing them to choose the search criteria:

▣ SOGUG Projects

Projects where SOGUG is the sponsor.

▣ CONTINUING EDUCATION AND TRAINING

- ▣ SCIENTIFIC SYMPOSIUM
- ▣ TRANSLATIONAL SYMPOSIUM
- ▣ COURSE IN PROSTATE AND BLADDER CANCER
- ▣ COURSE IN KIDNEY CANCER AND GERMINAL TUMOURS
- ▣ DISTANCE (ONLINE) TRAINING COURSES
- ▣ GRANTS
- ▣ OTHER

▣ RESEARCH AND CLINICAL TRIALS

- ▣ PROSTATE
- ▣ BLADDER
- ▣ KIDNEY
- ▣ TRANSLATIONAL
- ▣ OTHERS

▣ PROJECTS WITH PATIENTS

▣ INFRASTRUCTURE

▣ Collaboration Projects

Projects where SOGUG is a collaborator.

▣ CONTINUING EDUCATION AND TRAINING

▣ RESEARCH AND CLINICAL TRIALS

- ▣ PROSTATE
- ▣ BLADDER
- ▣ KIDNEY
- ▣ TRANSLATIONAL
- ▣ OTHER

▣ PROJECTS WITH PATIENTS

▣ INFRASTRUCTURE

▣ Projects Supported by SOGUG

▣ Projects in Collaboration with the SOGUG Foundation

Activity



5.1 Own Projects

Area of Infrastructure

Active	SOGUG-2016-INF(F)-1	SOGUG-2016-INF(F)-2	SOGUG-2016-INF-5	SOGUG-2016-INF-6
	Research Office José Ángel Arranz Arijá, MD Isabel Grau Miró	The SOGUG Foundation Enrique Gallardo Díaz, MD Aránzazu González del Alba Baamonde, MD Natalia Bellido de Lestable	Project Search Engine SOGUG WEBSITE Projects Begoña Pérez Valderrama, MD	SOGUG WEBSITE Project Martín Lázaro Quintela, MD
	SOGUG-2016-INF-7 Collaboration with the Germinal Group Miguel Ángel Climent Durán, MD	SOGUG-2016-INF-9 Review, updating and implementation of Standard Operating Procedures (SOPs) Begoña Pérez Valderrama, MD	SOGUG-2018-A-INF-4 Compliance Project with the European Regulation on Data Protection Natalia Bellido de Lestable	SOGUG-2019-INF-2 SOGUG PODCAST Begoña Pérez Valderrama, MD María José Méndez Vidal, MD
	SOGUG-2019-INF-4 SOGUG Positioning José Ángel Arranz Arijá, MD Enrique Gallardo Díaz, MD María José Méndez Vidal, MD	SOGUG-2019-INF-5 SOGUG-LATAM Cristina Suárez Rodríguez, MD	SOGUG-2019-INF-10 SOGUG INFO Begoña Pérez Valderrama, MD Silvia Martínez Cruz Natalia Bellido de Lestable	SOGUG-2021-INF-4 Network of Basic Research Centres (CIB) associated with SOGUG (CIB Network-SOGUG) Nuria Romero Laorden, MD José Ángel Arranz Arijá, MD Enrique Gallardo Díaz, MD María José Méndez Vidal, MD
	SOGUG-2022-INF-1 Satisfaction Survey Enrique Gallardo Díaz, MD Begoña Pérez Valderrama, MD	SOGUG-2022-INF-2 Account Auditing Aránzazu González del Alba Baamonde, MD Enrique Gallardo Díaz, MD	SOGUG-2022-INF(F)-3 Research with SOGUG 2022. FIC&T: SOGUG Clinical and Translational Research Meetings Julio Lambea Sorrosal, MD Nuria Romero Laorden, MD Aránzazu González del Alba Baamonde, MD	SOGUG-2022-INF-4 Bylaw Review Enrique Gallardo Díaz, MD Begoña Pérez Valderrama, MD
In Preparation	SOGUG-2019-INF-1 SOGUG APP Martín Lázaro Quintela, MD María José Méndez Vidal, MD	SOGUG-2019-INF-3 SOGUG Advisory Committee José Ángel Arranz Arijá, MD Enrique Gallardo Díaz, MD María José Méndez Vidal, MD	SOGUG-2019-INF-9 SOGUG Network of Information on Clinical Trials in Genitourinary Tumours Sergio Vázquez Estévez, MD	
Completed	SOGUG-2021-A-INF-2 Account Auditing 2021 José Ángel Arranz, MD Aránzazu González del Alba Baamonde, MD			

Area of Continuing Education and Training

Active	SOGUG-2016CET(OTH)-11	SOGUG-2019-CET(OTH)-3	SOGUG-2021-CET(OTH)-2	SOGUG-2020-CET(ONL)-4
	MUST READ Julio Lambea Sorrosal, MD Ovidio Fernández Calvo, MD	SOGUG Manual of Translational Oncology Nuria Romero Laorden, MD	1st SOGUG Translational Training Programme in Genitourinary Tumours (PROFIT) Nuria Romero Laorden, MD Aránzazu González del Alba Baamonde, MD	E-Learning in Prostate Cancer Ovidio Fernández Calvo, MD
In Preparation	SOGUG-2022-ECF(OTR)-6 Manual of Toxicities in Kidney Cancer Verónica Calderero Aragón, MD			
Completed	SOGUG-2022-ECF(CUR)-1 SOGUG 13th Course in Kidney Cancer and Germinal Tumours Ovidio Fernández Calvo, MD Gustavo Rubio Romero, MD María José Méndez Vidal, MD	SOGUG-2022-ECF(OTR)-2 SOGUG 3rd Review Conference of the American Congress of Oncology 2022 María José Méndez Vidal, MD Aránzazu González del Alba Baamonde, MD Begoña Pérez Valderrama, MD	SOGUG-2022-ECF(CUR)-3 SOGUG 11th Course in Prostate and Bladder Cancer Ovidio Fernández Calvo, MD Gustavo Rubio Romero, MD María José Méndez Vidal, MD	SOGUG-2022-ECF(OTR)-4 SOGUG 3rd Review Conference of the European Congress of Oncology 2022 María José Méndez Vidal, MD Aránzazu González del Alba Baamonde, MD Begoña Pérez Valderrama, MD
	SOGUG-2022-ECF(SIM)-5 SOGUG 13th Scientific Symposium María José Méndez Vidal, MD			

Area of Research and Clinical Trials

Active	SOGUG-2008-A-RCT(PRO)-1	SOGUG-2013-A-RCT(REN)-2	SOGUG-2016-P-RCT(BLD)-9	SOGUG-2016-A-RCT(PRO)-12
	Randomized, phase II clinical study of radiation therapy, hormone therapy, and chemotherapy with docetaxel versus radiation therapy and hormone therapy in patients with high-risk localized prostate cancer (stage III and IV) (QRT-SOGUG) Joan Carles Galcerán, MD	Circulating first-line markers in patients with advanced renal carcinoma or metastatic clear cell renal carcinoma Gaspar García Reynés, MD	Prospective study of the utility of liquid biopsy as a predictive and prognostic factor in patients with metastatic urothelial carcinoma in progression after platinum-based chemotherapy José Ángel Arranz Arijá, MD Begoña Pérez Valderrama, MD Urbano Anido Herranz, MD	Phase II trial evaluating olaparib maintenance in patients with castration-resistant prostate cancer (CRPC) after docetaxel treatment (IMANOL) María José Juan Fita, MD Miguel Ángel Climent Durán, MD

SOGUG-2016-A-RCT(PRO)-14	SOGUG-2017-A-RCT(BLD)-1	SOGUG-2017-P-RCT(BLD)-3	SOGUG-2017-A-RCT(BLD)-4	In Preparation	SOGUG-2019-RCT(OTH)(F)-2	SOGUG-2020-RCT(BLD)-11	SOGUG-2021-RCT(BLD)-2	SOGUG-2022-RCT(BLD)-1
<p>Randomized, multi-arm, multistage phase III trial of immunotherapy strategies in patients with hormone-sensitive prostate carcinoma: pilot phase (PROSTRATEGY) José Ángel Arranz Arija, MD Joan Carles Galcerán, MD Begoña Pérez Valderrama, MD</p>	<p>Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy in localized muscle-invasive bladder carcinoma treated with a bladder preservation approach (IMMUNOPRESERVE) Xavier García del Muro, MD</p>	<p>Impact of neoadjuvant chemotherapy on patients with histological variants of urothelial carcinoma of the bladder: a SOGUG retrospective analysis Albert Font Pous, MD Montserrat Domènech Santasusana, MD Ovidio Fernández Calvo, MD</p>	<p>Association of PD-L1 expression (in tissue) and different immune cytokines (in urine and blood) with the efficacy of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer (ATEZOBLADDER-PRESERVE) Sergio Vázquez Estévez, MD Ovidio Fernández Calvo, MD Cristina Núñez González, MD</p>		<p>The PRINCIS Project: Clinical Research Programme of Social Interest José Ángel Arranz Arija, MD Aránzazu González del Alba Baamonde, MD</p>	<p>SOGUG-NEOWIN: A phase 2, open label, multi-centre, multi-national interventional to evaluate the efficacy and safety of erdafitinib monotherapy and erdafitinib and cetrelimab combination as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) whose tumors express FGFR gene alterations Guillermo de Velasco Orla de Rueda, MD</p>	<p>Correlation between liquid biopsy proteomics and the Consensus Molecular Classification in metastatic bladder cancer. Developing a model for molecular clinical prognosis Sergio Vázquez Estévez, MD José Ángel Arranz Arija, MD Cristina Núñez González, MD</p>	<p>Treatment efficacy control and early detection of metastatic relapse by detecting circulating tumour DNA in patients with urothelial carcinoma of the bladder María José Méndez Vidal, MD</p>
SOGUG-2017-A-RCT(REN)-7	SOGUG-2018-A-RCT(REN)-2	SOGUG-2019-RCT(REN)-1	SOGUG-2019-RCT(PRO)-4	SOGUG-2022-RCT(PRO)-2	SOGUG-2022-RCT(REN)-4			
<p>SPRWEC study: Real-world evidence cabozantinib Cristina Suárez Rodríguez, MD</p>	<p>Phase II study of cabozantinib tolerability, safety and efficacy in metastatic renal carcinoma in aged fragile patients (CABOMAYOR) Miguel Ángel Climent Durán, MD</p>	<p>Prognostic value of PD-L1 in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors (PROANG) Emilio Esteban González, MD Clara Iglesias Gómez, MD Teresa Alonso Gordo, MD</p>	<p>Randomized, phase II study to assess the clinical utility of the prednisone-to-dexamethasone switch after initial biochemical progression in patients with metastatic hormone-sensitive prostate carcinoma treated with abiraterone (SWITCH) Nuria Romero Laorden, MD David Lorente Estellés, MD</p>	<p>Determining DDR mutations in a cohort of patients with mCRPC by liquid biopsy (ctDNA). Consistency with the germinal study and in tumour tissue Aránzazu González del Alba Baamonde, MD</p>	<p>SOGUG-ERWEC: European real-world evidence cabozantinib Cristina Suárez Rodríguez, MD</p>			
SOGUG-2019-RCT(REN)-5	SOGUG-2019-RCT(REN)-6	SOGUG-2020-RCT(BLD)-1	SOGUG-2020-RCT(OTH)-4	Completed	SOGUG-2010-A-RCT(REN)-1	SOGUG-2013-A-RCT(PRO)-3	SOGUG-2016-A-RCT(REN)-10	SOGUG-2020-RCT(REN)-10
<p>Clinical and molecular determinants in personalised treatment with immunotherapy in renal cell carcinoma Juan Ruiz Bañobre, MD</p>	<p>Biomarker identification study in sequential samples from patients with renal carcinoma José Luis Pérez Gracia, MD Cristina Suárez Rodríguez, MD</p>	<p>AUREA: a study of split cisplatin/gemcitabine and atezolizumab in urothelial carcinoma Guillermo de Velasco Orla de Rueda, MD</p>	<p>Observational, retrospective-prospective study in patients with genitourinary tumours presenting with COVID-19 infection (SOGUG-COVID-19) Sergio Vázquez Estévez, MD Aránzazu González del Alba Baamonde, MD Miguel Ángel Climent Durán, MD Javier Puente Vázquez, MD Natalia Vidal Cassinello, MD</p>		<p>Open, prospective, multi-centre phase I/II clinical trial to determine the recommended dose in phase I and the efficacy of pazopanib in combination with interferon alpha 2a in phase II, in patients with advanced renal carcinoma Xavier García del Muro, MD Ignacio Durán Martínez, MD José Luis Pérez Gracia, MD</p>	<p>Maintenance of abiraterone acetate in combination with docetaxel after disease progression to abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC). A phase II randomised trial (ABiDO) Miguel Ángel Climent Durán, MD</p>	<p>Phase II study to assess the efficacy and safety of treatment with sunitinib in patients with metastatic renal carcinoma who have progressed to first-line immunotherapy (INMUNOSUN) Enrique Grande Pulido, MD</p>	<p>TIVOChip Enrique Gallardo Díaz, MD Cristina Suárez Rodríguez, MD</p>
SOGUG-2021-RCT(PRO)-1	SOGUG-2021-RCT (BLD)-4	SOGUG-2021-RCT(BLD)-5	Cancelled	SOGUG-2022-IEC(VEJ)-3				
<p>Screening tools for elders frailty with mCRPC treated with docetaxel and without previous chemotherapy (FRAGDOC study) María José Molina Garrido, MD</p>	<p>Phase II non randomized clinical trial of nivolumab/ ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer (VEXILLUM) Guillermo de Velasco Orla de Rueda, MD</p>	<p>Multicentric, observational study to evaluate real-world data of avelumab maintenance therapy for advanced or metastatic urothelial carcinoma; a SOGUG study Ovidio Fernández Calvo, MD Áurea Molina, MD</p>		<p>SOGUG-CHAMALEON: A phase II study of adaptative dose of avelumab in advanced and/or urothelial carcinoma patients Alfonso Gómez de Liaño, MD Guillermo de Velasco Orla de Rueda, MD</p>				

Area of Patients

Active

SOGUG-2017-A-PTS-1 50/50 Project Sergio Vázquez Estévez, MD	SOGUG-2019-PTS-1 SOGUG CONTIGO Sergio Vázquez Estévez, MD	SOGUG-2019-PTS(F)-3 Expert Patient in Bladder Cancer Sergio Vázquez Estévez, MD	SOGUG-2022-PAC(F)-1 Expert Patient in Prostate Cancer Martín Lázaro, MD Verónica Calderero Aragón, MD
--	--	--	---

5.2 SOGUG Collaboration Projects

Area of Infrastructure

Active

SOGUG-2019-COL(F)-5 Integration of innovation project in the management of patients with genitourinary tumours (I2GU) José Ángel Arranz Arija, MD Enrique Gallardo Díaz, MD Miguel Ángel Climent Durán, MD	SOGUG-2022-COL(F)-8 Integration of innovation project in the management of patients with genitourinary tumours (I2GU). Prostate carcinoma (ENFOCADOS) Aránzazu González del Alba Baamonde, MD María José Méndez Vidal, MD Enrique Gallardo Díaz, MD	SOGUG-2022-COL-9 Training course in urothelial carcinoma for sales network Ovidio Fernández Calvo, MD Gustavo Rubio Romero, MD Begoña Pérez Valderrama, MD
---	--	---

Area of Continuing Education and Training

Active

SOGUG-2022-COL-10 V940-004 Campus Horizon: 3rd edition of the Master's Degree in Integral Immuno-oncology Aránzazu González del Alba Baamonde, MD	SOGUG-2022-COL-11 1st UC Synergy: Networking Portugal and Spain Aránzazu González del Alba Baamonde, MD	SOGUG-2022-COL-12 1st Course in Immunotherapy for Urothelial Carcinoma Aránzazu González del Alba Baamonde, MD Begoña Pérez Valderrama, MD	SOGUG-2022-COL-13 SEOM-SOGUG Guide for Renal Carcinoma Aránzazu González del Alba Baamonde, MD
--	--	--	---

In Preparation

SOGUG-2020-COL-1 1st Course of Pharmacoconomics applied to Genitourinary Tumours Ovidio Fernández Calvo, MD Begoña Pérez Valderrama, MD	SOGUG-2022-COL-14 Online course in toxicities in urothelial cancer Ovidio Fernández Calvo, MD
---	--

Completed

SOGUG-2021-COL-3 SEOM-SOGUG Guide for Carcinoma of the Bladder Project José Ángel Arranz Arija, MD	SOGUG-2022-COL-3 SOGUG 13th Review Conference of the American Congress of Genitourinary Tumours 2022 María José Méndez Vidal, MD Begoña Pérez Valderrama, MD
---	--

Area of Research and Clinical Trials

Active

SOGUG-2014-A-COL-2 Invasive bladder cancer: Toward precision medicine Francisco X. Real Arribas, MD	SOGUG-2019-A-COL-8 A phase III, multicentre, randomised open-label study of atezolizumab in combination with cabozantinib in patients with renal cell carcinoma who experienced disease progression during or after check point inhibitor treatment (CONTACT03) José Ángel Arranz Arija, MD	SOGUG-2016-A-COL-11 A phase III, multicentre, randomised, placebo-controlled study of atezolizumab (anti-PD-L1 as monotherapy and in combination with platinum-based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma (IMVIGOR 130) Sergio Vázquez Estévez, MD José Ángel Arranz Arija, MD Enrique Gallardo Díaz, MD Begoña Pérez Valderrama, MD Aránzazu González del Alba Baamonde, MD	SOGUG-2018-A-COL-3 ODM-201 maintenance therapy in patients with metastatic castration-prostate cancer previously treated with novel hormonal agents and non-progressive disease after subsequent treatment with a taxane: A multicentre, randomised, double-blind, placebo-controlled phase II trial (SAKK 08/16) Aránzazu González del Alba Baamonde, MD Javier Cassinello Espinosa, MD
SOGUG-2020-A-COL-1 Phase II study of neoadjuvant immune checkpoint inhibitors in urothelial cancer (ABACUS-2) Alejo Rodríguez-Vida Rodríguez, MD			

Completed

SOGUG-2020-A-COL-2 A phase II study investigating preoperative bintrafusp alfa in operable urothelial carcinoma of the bladder (PEBBLE) Alejo Rodríguez-Vida Rodríguez, MD	SOGUG-2022-COL-1 Immunotherapy in patients with cancer and autoimmune diseases Cristina Suárez Rodríguez, MD Enrique Gallardo Díaz, MD VHIO	SOGUG-2022-COL-5 PEACE-6: International, phase 3 trial, evaluating the efficacy and safety of standard of care (SOC) with or without tailored therapy in men with metastatic prostate cancer Joan Carles Galcerán, MD GETUG	SOGUG-2022-COL-9 Randomised clinical trial of first-line IO/IO vs. IO/TKI in patients with metastatic kidney cancer Cristina Suárez Rodríguez, MD Laurence Albiges, MD GETUG
SOGUG-2022-COL-10 Combination of darolutamide and stereotactic radiation therapy in patients with castration resistant prostate cancer and oligometastases on functional imaging Joan Carles Galcerán, MD GETUG			

Area of Patients

Active

SOGUG-2022-COL-4

Nutrition in Kidney Cancer
Sergio Vázquez Estévez,
MD

SOGUG-2022-COL-8

Expert Patient in
Kidney Cancer II
Sergio Vázquez
Estévez, MD
Martín Lázaro Quintela, MD
Verónica Calderero
Aragón, MD

In Preparation

SOGUG-2022-COL-7

PODCAST for patients:
Quality of life in kidney
cancer
Martín Lázaro Quintela, MD
Verónica Calderero
Aragón, MD
María José Méndez
Vidal, MD
Begoña Pérez
Valderrama, MD

SOGUG-2022-COL-11

Guide for patients with
urothelial carcinoma
Martín Lázaro Quintela, MD
Verónica Calderero
Aragón, MD

5.3 Projects Supported by SOGUG

In 2022, 22 endorsements were requested and granted.

8th BEST-GU VIRTUAL

Club of GU Analysis

4th Spanish Symposium on Precision Oncology

Kidney Cancer Awareness Campaign: “De Viva Voz”

2022 RAGM Symposium: Recent Advances in Genitourinary Malignancies

Spanish Prostate Meeting

Preceptorship in the Management of Advanced Prostate Cancer: A Multi- Disciplinary Approach

1st Conference to Build Bridges in Prostate Cancer

2nd Conference in Rare Histologies in Genitourinary Tumours

The HOPE Project

ADC sessions in Oncology 2022

5th Conferences on Translational Research in Urological Tumours

5th Galician-Asturian post-CAO, post-ESMO Meeting on Genitourinary Tumours

E-PIMUC (E-Learning Pills on Immunotherapy in Urothelial Cancer) Online Training Programme

3rd UC Annual Course: Emerging Personalised Therapies in the Management of Urothelial Carcinoma

Advances in Molecular Biology of Prostate Cancer

7th Forum "Medical Oncology in 3 days"

Spanish Educational Meeting in virtual format: “RCC (Renal Cancer Challenge) in Early Disease”

World Bladder Cancer Awareness Month Campaign 2022

Prostate Cancer Lives Matter: 2nd Edition

V Optimizing Immunotherapy 5th Spanish Symposium on Precision Oncology

5.4 Education: Courses, Conferences and Grants

One of the main sources of learning is the exchange of knowledge that occurs when professionals meet. For this reason, SOGUG organises many symposiums and conferences, where experiences that make us grow professionally are shared. On this third year of the COVID-19 pandemic, we have already organised a few in-person events, such as SOGUG 11th Course in Prostate and Bladder Cancer and SOGUG 13th Scientific Symposium, both held in Madrid.

Courses

SOGUG 13th Course in Kidney Cancer and Germinal Tumours

Virtual, March 9 and 10, 2022
21 speakers, coordinators, moderators, and tutors
185 persons registered

SOGUG 13th Review Conference of the American Congress of Genitourinary Tumours of 2021

Virtual, March 2, 2022
10 speakers, coordinators, and moderators
165 persons registered

SOGUG 3rd Review Conference of the American Congress of Oncology of 2022

Virtual, June 22, 2022
11 speakers, coordinators, and moderators
124 persons registered

SOGUG 11th Course in Prostate and Bladder Cancer

Madrid, September 30 and October 1st, 2022
35 speakers, coordinators, moderators, and tutors
142 persons registered

3rd Review Conference of the European Congress of Medical Oncology

Virtual, October 5, 2022
11 speakers, coordinators, and moderators
104 persons registered

Symposium

SOGUG 13th Symposium

In-person and virtual format
November 16-18, 2022
42 speakers and moderators
477 registrations: 249 (virtual format)
and 228 (in-person format)

It should be noted that all the people registered gave this hybrid edition of the Symposium excellent scores.

Score (0-5)	4.65
Scientific content	4.71
Quality of speakers	4.38
Usability of the platform	4.53
Organisation of the conference	4.71
To what extent would you recommend the webinar to your professional colleagues?	

Online Courses

It is an interactive learning platform in the field of genitourinary tumours (renal, prostate, and bladder carcinoma).

During 2022, a new edition of the distance training course in prostate carcinoma has been prepared.

Multi-Disciplinary Meetings

1st UC Synergy: Networking Portugal and Spain

Virtual, November 22, 2022
8 speakers and moderators
66 persons registered



5.5 Scientific activity

Publications

SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021).

Valderrama BP, González del Alba A, Morales Barrera R, et al. Clin Transl Oncol 2022 Apr; 24(4):613-624

A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial. Climent MA, Font A, Durán I, et al. Eur J Cancer. 2022 Nov; 175:110-119.

Management of patients with metastatic bladder cancer in the real-world setting from the multi-disciplinary team: current opinion of the SOGUG multi-disciplinary working group.

González del Alba A, Conde Moreno AJ, García Vicente AM, et al. Cancers (Basel) 2022; 14(5):1130.

Advances in transversal topics applicable to the care of bladder cancer patients in the real-world setting.

Garrido Siles M, López Beltrán A, Pelechano P, et al. Cancers (Basel) 2022;14 (16): 3968.

Communications for congresses

Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: an interim analysis of the ATEZOBLADDER-PRESERVE PHASE II TRIAL (SOGUG-2017-A-RCT(BLD)-4)
Vázquez S, Fernández O, Bonfill T, et al. J Clin Oncol 2022;40(suppl_16) 4588-4588.

Comprehensive molecular characterization of

muscle invasive bladder cancer (MIBC) treated with durvalumab plus olaparib in the neoadjuvant setting: NEODURVARIB TRIAL.
Rodríguez Moreno JF, Ruiz Llorente S, Velasco G, et al. J Clin Oncol;40(suppl_6) 546-546.

Atezolizumab (ATZ) with split-doses of cisplatin plus gemcitabine in patients with locally advanced or metastatic urothelial carcinoma (SOGUG-AUREA): A multicentre, single-arm phase II trial.
De Velasco G, García Carbonero I, Esteban E, et al. Ann Oncol 2022;33 (suppl_7) S1333.

Pilot study to assess the safety and efficacy of cabozantinib in frail elderly patients with metastatic renal carcinoma (CRM+). Preliminary results from the CABO-MAYOR-SOGUG study.
Climent MA, Sánchez-Escribano R, Llabres E, et al. SEOM 2022.

Prognostic value of pd-1 in patients with metastatic renal cell carcinoma (MRCC) treated with antiangiogenic first-line drugs (PROANG-SOGUG STUDY).

Iglesias C, Blanco V, García Domínguez R, et al. Ann Oncol 2022;33 (suppl_ 7) S1220-S1221.

5.6 Summary of activities by committee

Event coordination committee

The event coordination committee has been an active part of all scientific committees and scientific meetings organised by SOGUG. In collaboration with the staff of SOGUG and the various committees involved in each event, mainly the education committee, this committee has coordinated and monitored the preparation of the meeting calendar, the assessment of candidates, the scientific programmes, the selection of moderators and speakers, the logistic organisation, and the relation with sponsor companies in communication campaigns associated with them to keep members informed.

This committee is, again, ensuring the participation of a higher number of members as speakers and moderators according to territorial equality and quality of the contents.

The 13th edition of the **Course in Kidney Cancer and Germinal Tumours** and the **11th Course in Bladder and Prostate Cancer** have been, again, a success, and both are still seeing a significant increase in students compared with previous editions, which is proof of the increasing interest of our members in the group's activities.

On March 2nd, **SOGUG 13th Review Conference of the American Congress of Genitourinary Tumours** was held, coordinated by Dr. Méndez Vidal and Dr. Pérez Valderrama, and on June 22nd, the **3rd Review Conference of the American Congress of Oncology** was organised.

On September 15, **SOGUG 3rd Review Conference of the European Congress of Oncology** took place, which sparked a lot of interest.

On November 16-18, 2022, **SOGUG 13th SCIENTIFIC SYMPOSIUM** was held in virtual and in-person format at the NH Eurobuilding Hotel, in Madrid, and is, without a doubt, the event that sparks the most interest from the group. On this occasion, we had the opportunity to meet again and, once more, we had renowned speakers of national and international prestige. A total of 477 persons registered for the event and gave it an excellent score overall.

Continuing Education Committee

The Continuing Education committee wants to give continuity to a comprehensive training programme in the area of genitourinary cancer. We have managed to get it recognised by all specialist registrars and GP registrars of Medical Oncology in Spain. It is our wish to keep encouraging and promoting training for GP registrars and specialist registrars in the clinical area and in basic and translational research.

The following events have taken place:

- **13th Review Conference of the American Congress of GU Tumours**, March 2, 2022.
- **SOGUG 13th Course in Kidney Cancer and Germinal Tumours**, March 9 and 10, 2022.
- **3rd Review Conference of the American Congress of Oncology**, June 22, 2022.
- **SOGUG 11th Course in Prostate and Bladder Cancer**, September 30 and October 1, 2022.
- **SOGUG 3rd Review Conference of the European Congress of Oncology**, September 15, 2022.
- **SOGUG 13th Scientific Symposium**, November 16-18, 2022.

Currently, the grant programme has been redefined to allow a larger number of members to participate if they wish to do so.

The 1st UC SYNERGY: Networking Portugal and Spain meeting was a virtual event organised by SOGUG in collaboration with Astellas, which was held on November 22, 2022 with speakers and attendants from both countries. At this meeting, coordinated by Dr. Arancha González del Alba and Dr. Mário Fontes e Sousa, urothelial carcinoma was reviewed and updated with the participation of Spanish and Portuguese speakers.

During 2022, we continued the MUST READ project of bibliographic updating after confirming the great interest sparked by this activity through a survey completed by all members. In this project, four members of SOGUG review the best publications from journals with a higher impact on Genitourinary Oncology on a quarterly basis, and draft a summary and a brief critical assessment, which is sent to all members and is published in our website.

Some significant numbers of the MUST READ project:

Members who have participated as reviewers since the project started in 2018	73
Members who have participated as reviewers in 2022	16
Members who have been reviewers more than once	13
Reviews published in 2022.*	Over 200

**Thousands of articles have been reviewed to select those that were published.*

Communication, Web, and Social Media Committee

The Communication, Web, and Social Media committee wants to make the activities carried out by the group known to SOGUG members, the scientific community, patients and other settings, such as the press, companies, etc., in order to expand the group's mission, be a benchmark in our field and bring us all closer.

For that reason, we had already created a Twitter (@sogug1) and LinkedIn profile and, this year, we have created new profiles, which we intend to invigorate:

- A Twitter profile focused on patients (@ContigoSogug) created jointly with the Activities with patients committee and intended to give visibility to the activities carried out in this area.
- A Facebook profile named "SOGUG Contigo," with the purpose of making articles and the group's activities known, and also focused on the activities carried out with patients.
- Another booming social network is Instagram, where an account has also been created, which is particularly intended to give visibility to meetings, training courses, etc.

We are also working to consolidate the previously created accounts. In fact, the @sogug1 account already has more than 2,000 followers and over 6,700 tweets. During 2022, the number of followers in all our social media accounts has increased.

We currently have:

LinkedIn: 287 followers
Facebook SOGUG Contigo: 21 followers
Twitter SOGUG: 2400 followers
Twitter SOGUG Contigo: 116 followers
Instagram SOGUG Contigo: 40 followers

During 2020, some changes had been made in SOGUG website, which were consolidated in 2021, making it a much more visual and dynamic platform, with the inclusion of new sections.

During 2023, we will develop a Communication Plan to globally coordinate and improve the group's social ways of communication. In this sense, we have also contacted different audiovisual communication sectors to offer SOGUG as a benchmark regarding genitourinary tumour pathologies, emphasising our scientific and training contribution (publication of articles, scientific events, or news related with the field of this pathology). This Communication Plan will include financial resources with each event to communicate.

This committee collaborates with others, including the patients' committee, with which it is creating a group of patients with kidney cancer where they can express their doubts and comments.

Lastly, this committee has drafted a proposal with the criteria for granting "SOGUG Scientific Support", which requires the training programme requesting said support to have scientific quality and be aligned with the objectives and goals of the group. This support can be requested by those people organising a scientific event or preparing any document of interest for oncology professionals or the general population. The set of criteria will be accessible to the public on our website.

In 2022, an institutional collaboration agreement has been established with the Prostate Cancer Foundation and its subsidiary UroToday, which has translated into the first coverage performed by UroToday about SOGUG International Symposium of November 2022, as well as an associated event with prostate cancer patients. This agreement intends to cover the different SOGUG events and help provide a wider international dissemination, with special emphasis in the Latin American setting. In this sense, an annual event has been planned between SOGUG and Latin America with the intention of starting it in 2023, which is particularly focused on news about prostate, bladder and kidney cancer.

Interdisciplinary Relationships Committee

Coordinated multi-disciplinary work is essential. SOGUG must look after and work to make this a reality and not only a statement of intent. It is important to build relationship bridges, exchange dynamics, and work jointly with the other healthcare specialities involved in the diagnosis, treatment, follow-up and care of patients with genitourinary cancer.

During 2022, the I2GU Project (Integration of Innovation in the Management of Patients with Genitourinary Tumours) was continued, in collaboration with AZ and the participation of other specialists involved in the diagnosis and treatment of this disease, in addition to SOGUG members: urologists, radiation oncologists, pathologists, and specialists in imaging techniques and in pharmacy management. The objective has been to try to identify which are the most important lines of innovation in the different areas for each speciality, set a common ground, and try to integrate them in the care process, to make the treatment of our patients increasingly more multi-disciplinary. The first part of the project was focused on vesical carcinoma. Two articles have been published in 2022:

- González-Del-Alba A, Conde-Moreno AJ, García Vicente AM, González-Peramato P, Linares-Espinós E, Climent MÁ, The SOGUG Multidisciplinary Working Group. Management of Patients with Metastatic Bladder Cancer in the Real-World Setting from the Multidisciplinary Team: Current Opinion of the SOGUG Multidisciplinary Working Group. *Cancers (Basel)*. 2022 Feb 23;14(5):1130. doi: 10.3390/cancers14051130
- Garrido Siles M, López-Beltran A, Pelechano P, García Vicente AM, Gironés Sarrió R, González-Haba Peña E, Rodríguez Antolín A, Zapatero A, Arranz JÁ, Climent MÁ; Spanish Oncology Genitourinary Multidisciplinary Working Group. *Advances in Transversal Topics*

Applicable to the Care of Bladder Cancer Patients in the Real-World Setting. *Cancers (Basel)*. 2022 Aug 17;14(16):3968. doi: 10.3390/cancers14163968. PMID: 36010964; PMCID: PMC9406347.

The initial phase of the ENFOCA2 project, which is focused on prostate cancer, has been set in motion. We are facing a series of challenges requiring a multi-disciplinary approach, so we can offer the best possible benefit for these patients. These challenges include the lack of knowledge by the general population regarding the seriousness of the disease and the significance of preventative tests, the physical and social barriers to male stigmas, and the need to implement measures that facilitate an early and individualised diagnosis and treatment.

The ENFOCA2 project has been developed to identify current and future clinical challenges in the management of prostate cancer requiring a multi-disciplinary approach, to listen and give a voice to patients with prostate cancer to empower them and make them allies in the treatment of their disease, and to increase awareness about prostate cancer among the population. This project has the multi-disciplinary collaboration of all professionals involved in the management of patients with prostate cancer, and it is also performed under the coordination of SOGUG and the AstraZeneca & MSD alliance.

Clinical and translational research

SOGUG is a Spanish benchmark in clinical and translational research, with human resources and systematised work at its foundation, both to promote clinical and translational research and to support any research project proposed by each and every one of the members, from ideas in their early stages to projects with a definite design.

Translational research arises from the need to strengthen the links between basic research and clinical research. This union makes it possible to take the technique and advances of basic research to patients, increasing their impact on clinical practice, aligned with the values that SOGUG identifies with.

The SOGUG group is mainly made by medical oncologists, who essentially care for their patients, although many are also regularly involved in clinical research projects. However, the field of basic research is oftentimes far from the reality of the medical oncologist. At SOGUG, we believe that, by strengthening communication and bringing clinical and basic researchers closer, we can improve the quality of GU research in our country and increase the dissemination of ideas.

During 2022, we have made progress in the development of a translational research plan based on our two essential objectives:

1. Bring basic research and clinical research in genitourinary tumours closer.

- In 2021, a [Network of Basic Research Centres associated with SOGUG \(CIB Network-SOGUG\)](#) was created after contacting basic and translational researchers from all over the country who showed an interest in collaborating with our group. The network of basic research centres in genitourinary tumours that collaborates with SOGUG

is an open network.

We are working on making it known through the group's website, where it will be presented in the form of an interactive map, and each collaborating centre will have a drop-down menu showing a small CV of each laboratory. Any basic research centre with experience in the field of genitourinary tumours or in basic research techniques applicable to this field will be a candidate to be part of our network of collaborating centres. At SOGUG, we will ensure the feasibility of all submitted research projects, and promote team, multi-disciplinary and coordinated work.

- We are working on scheduling [daily clinical and translational meetings](#) in a forum to allow clinical researchers of SOGUG and researchers from the CIB Network-SOGUG to discuss projects.
 - We are preparing a programme for the next SOGUG Forum of Clinical and Translational Research, 2023 edition, that seeks a motivating approach for research and to discuss research from different perspectives: researchers, clinicians, patients associations, the pharmaceutical industry, etc.
 - In 2021, [Spanish Research Projects \(PINs\)](#) were selected. The goal of the committee will be to drive these PIN projects and continue them in consecutive years.
- ### 2. Improve Translational Research theoretical-practical training with the support of the Education and Training Committee.
- We have carried out the [Translational Research in Genitourinary Oncology Training Programme \(PROFIT\)](#). It is an online training programme for top-level scientists, many of them members of the

Clinical and translational research

CIB Network-SOGUG. Registrations open from December 2021. Six modules organising the key points of translational research in genitourinary tumours:

- Block 1: Obtainment of samples: biobanks and methodology.
- Block 2: Sequencing and genic expression: from DNA to the cell.
- Block 3: Models in research: from in vitro to in vivo.
- Block 4: The role of biocomputing.
- Block 5: GU tumour biomarkers.
- Block 6: Molecular profiles in GU tumours.
- Workshop on the development of translational research projects, May 17, 2023.

A total of 140 people registered with the help of five sponsors from the pharmaceutical industry and the scientific support of SEOM. Furthermore, 15 grants were awarded to facilitate the registration of SOGUG members. The course is certified by the European University of Madrid. The training programme will end on June 30, 2023.

- In parallel, we are working on a Translational Research Manual that can serve as a consultation and support material for all SOGUG members interested in this area, supplementary to the PROFIT Programme and readily accessible.

Activities with patients

During 2022, we continued with the **SOGUG CONTIGO** (SOGUG WITH YOU) project, intended to regularly send important information and news on genitourinary tumours to communication media and patients associations.

The Expert Patient project was created in collaboration with the AECC (Spanish Association Against Cancer) and included a group of patients diagnosed with different aspects of this oncological pathology. The **EXPERT PATIENT IN PROSTATE CANCER** project gathered a group of expert patients in this type of tumour based on the previous group already formed, in order to identify and cover their needs, both from the medical and psychosocial perspectives. Seven meetings were held in which different subjects were discussed, from diagnoses and symptoms to psychosocial aspects and the different treatments available.

Regarding the **EXPERT PATIENT IN BLADDER CANCER** project, which started the year before, we continued to hold two more meetings with patients and a psycho-oncologist from the AECC.

Collaboration with BMS has been started to work on a project called **ORCHESTRA**, focused on facilitating access to information for patients with kidney cancer.

Another activity associated with prostate cancer, continuing that performed in past years, was that of the **AREA SPECIFICALLY INTENDED FOR PATIENTS AND CARERS WITHIN SOGUG 12TH SYMPOSIUM**, which was successfully carried out the last day of the event, with a high participation and interaction from all attendants.

Also, **SOGUG 50/50** projects, which had been suspended during the pandemic, were restarted, with the first one of this new phase being held in person in Gran Canaria.

Lastly, a programme focused on exercise and nutrition for patients with genitourinary tumours (*Nutriactivos*) is being developed in collaboration with Ipsen.

The SOGUG Foundation



The SOGUG Foundation

The SOGUG Foundation (FSOGUG) was formed in Madrid, in March of 2017, with the objective of driving, promoting and favouring activities associated with research, development, and innovation in the field of genitourinary tumours, with quality, excellence, transparency, and continuously oriented to preventing this disease and improving treatment and quality of life of patients.

The Foundation is organised as follows:

Governance

Board of Trustees

Highest governance, management and representative body.

Executive Committee (optional)

Representation of the Board of Trustees. Monitoring and follow-up functions. Five people (two committee members chosen by the Board of Trustees from their own numbers, the president, the vice president and the secretary).

Management

Manager or Director

Appointed by the Board of Trustees. Managerial, financial-administrative and HR functions.

THE FOLLOWING ARE EX OFFICIO MEMBERS OF THE BOARD OF TRUSTEES:

- The current president of SOGUG.
- The current vice president of SOGUG.
- The current secretary of SOGUG.
- The past president of SOGUG.
- The past vice president of SOGUG.

Advisory Body

The Board of Trustees can decide to create advisory bodies and provide them with functions.

Council of Protectors

Advisory Committees

Committee of Research, Training and Quality

Support

Financial-Administrative and Human Resource Support

Based on the Foundation bylaws, at least two committee members from the Board of Directors of SOGUG will be chosen by it to be part of the Board of Trustees. Other potential members may be chosen on the condition that, for each new member of the Board of Trustees outside of the Board of Directors of SOGUG, the latter will designate an additional committee member to be part of the former.

After renewing the Board of Directors of SOGUG in November 2021, the Board of Trustees was also renewed. Its current composition in 2022 is as follows:

President	Aránzazu González del Alba Baamonde, MD
Vice President	Cristina Suárez Rodríguez, MD
Secretary	Begoña Pérez Valderrama, MD
Past President	José Ángel Arranz Arija, MD
Past Vice President	Enrique Gallardo Díaz, MD
Committee members	María José Méndez Vidal, MD Martín Lázaro Quintela, MD Ignacio Peláez Fernández, MD
Member outside the BoD	Sergio Vázquez Estévez, MD

Activities of the Foundation

During 2022, we have carried out various activities of the SOGUG Foundation in the three main areas of performance,

Research

One of the objectives of SOGUG is to promote the development of research programmes in the field of genitourinary tumours. FSOGUG facilitates the obtainment of funds intended for this end.

In this sense, during 2022, we have continued supporting the five winning projects of the 1st Ideas Competition of 2019, funded by FSOGUG, as well as the winners of the 2nd Edition of 2021, which included a collaboration from Janssen that was added to FSOGUG funds:

- Impact of neoadjuvant chemotherapy on patients with histological variants of urothelial carcinoma of the bladder: A SOGUG retrospective analysis. Principal Investigators: Montserrat Domènech Santasusana, MD, Ovidio Fernández Calvo, MD, and Albert Font Pous, MD. Grant awarded in 2019.

- Prospective study of the utility of liquid biopsy as a predictive and prognostic factor in patients with metastatic urothelial carcinoma in progression after platinum-based chemotherapy. Principal Investigator: Begoña Pérez Valderrama, MD. Grant awarded in 2019.

- Randomised, phase II study to assess the clinical utility of prednisone-to-dexamethasone switch after initial biochemical progression in patients with metastatic hormone-sensitive prostate cancer treated with abiraterone. Principal Investigators: Nuria Romero Laorden, MD, and David Lorente Estellés, MD. Grant awarded in 2019.

- Clinical and molecular determinants in personalised treatment with immunotherapy in renal cell cancer. Principal Investigator: Juan Ruiz Bañobre, MD. Grant awarded in 2019.

- Biomarker identification study in sequential samples from patients

with kidney cancer. Principal Investigators: Cristina Suárez Rodríguez, MD, and José Luis Pérez Gracia, MD. Grant awarded in 2019 and extended in 2021.

- Bio-SWITCH: Identifying the biological bases of the prednisone-to-dexamethasone switch after initial biochemical progression in patients with metastatic hormone-sensitive prostate cancer treated with abiraterone. Principal Investigators: Nuria Romero Laorden, MD, and David Lorente Estellés, MD. Grant awarded in 2021.

- Molecular profile associated with the benefit of immunotherapy in patients with hormone-sensitive prostate cancer: Translational studies associated with the PROSTRATEGY clinical trial. Principal Investigators: José Ángel Arranz, MD, Begoña Mellado, MD, and Óscar Reig, MD. Grant awarded in 2021.

- Determining DDR mutations in a cohort of patients with mCRPC by liquid biopsy (ctDNA). Consistency with the germinal study and in tumour tissue. Principal Investigator: Aránzazu González del Alba, MD. Grant awarded in 2021.

- Liquid biopsy-based proteome classification of muscle invasive bladder cancer. Principal Investigator: Sergio Vázquez Estévez, MD. Grant awarded in 2021.

- Treatment efficacy control and early detection of metastatic relapse by detecting circulating tumour DNA in patients with urothelial carcinoma of the bladder. Principal Investigator: María José Méndez Vidal, MD. Grant awarded in 2021.

FIC&T



During 2022, we have also continued to support the two projects submitted in the Clinical and Translational Research Forum of 2020, also known as PIN (for its Spanish initials, *Proyectos de Investigación Nacional*, or Spanish Research Projects).

- Screening tools for frailty in elderly patients with metastatic castration-resistant prostate cancer treated with first-line docetaxel. FRAG-DOC study. Project coordinated by Dr. María José Molina. (Funded by FSOGUG).
- Characterization of the histological consensus molecular classification subtypes based on liquid biopsy, and development of a prognosis model in metastatic bladder cancer. Project coordinated by Dr. Sergio Vázquez Estévez. (Partially funded by the FSOGUG).

Since both projects are classified as PINs, they will be developed as strategic lines of research of SOGUG in the following years.

Activities with Patients

A central component of FSOGUG is the development and promotion of activities with patients in collaboration with the SOGUG group. In this sense, during 2022, we have continued with the activities associated with the **Expert Patient in Kidney Cancer** project, in collaboration with ALCER and with the support of IPSEN.

We have also continued the **Expert Patient in Bladder Cancer** project, started in 2021 in collaboration with the AECC.

Furthermore, in June 2022, on the occasion of the World Day of Prostate Cancer, we introduced the **Expert Patient in Prostate Cancer** project with learning activities, between September and November.

In 2022, SOGUG, through the FSOGUG, has started a collaboration with UroToday and the Prostate Cancer Foundation, based in California, that funds research to prevent and cure prostate cancer. Its President and CEO, Charles Ryan, MD, attended the 13th Annual Symposium and actively collaborated in the **Event with Patients**, held on November 18, later sharing his experience at the foundation he presides. The event, which was attended by patients and their relatives, as well as by representatives of the National Federation of Associations ALCER (Association for the Fight Against Kidney Diseases) and the European Patients' Academy, was hosted by reporter Macarena Berlín.

Fortunately, at the end of 2022, we were able to reactivate in-person sessions with patients and their relatives through SOGUG 50/50 project, with a meeting at Las Palmas on December 14. We intend to continue this project in 2023.

Other projects

The PRINCIS (*PRoyecto de Investigación Clínica de Interés Social, or Clinical Research Project of Social Interest*) project

The purpose of this project is to develop scientific programmes in the field of genitourinary tumours that focus on clinical evidence (real-life data, post-authorisation adjustment) based on patients' individual characteristics.

To better identify the social interest needs in our country based on those criteria, the design, objectives and development of this programme will be carried out in collaboration with Spanish regulatory authorities, particularly the Spanish Agency of Medicines and Medical Devices (AEMPS, for its Spanish initials), which has already shown an interest in this project. The final goal will be to improve and optimize the management of patients with genitourinary tumours in our country.

Dossier of the SOGUG Foundation

In 2019, a specific dossier for FSOGUG was created for the different agents that could be interested in collaborating with the Foundation: associations, foundations, and patients, as well as the pharmaceutical industry, companies, other institutions, and the society in general. The purpose of the dossier is to report the reason of being of FSOGUG, its objectives and activities, including forms and typology of the collaborations, as well as enable the obtainment of funds. This dossier is regularly updated to adapt to specific needs of current times.

Financial Balance



Financial Balance

The most relevant facts of the economic activity of the entity during the fiscal year 2022 are detailed below:

The fiscal year ends with a total revenue of €2,352,639, along the same line as that obtained in recent years.


Of the total income of the fiscal year 2022, 63% corresponds to Research, and the remaining 37%, to Continuing education, Activities with patients and other projects. It is important to highlight that the revenue obtained in 2022 for Activities with patients only represents 1% of the total revenue obtained. Most of these projects have been carried out with our own funds, given the difficulty to obtain external funding.

Regarding expenses, they have evolved similarly to revenue, therefore the surplus of the fiscal year allows us, once again, to increase the coverage of the structure, as well as current and future expenses of the group. All this contributes to continue with our plans to promote and disseminate the activities

that are the goals of the entity in the field of research, not only clinical research, but also basic and translational research, the continuing education of dedicated to these pathologies, and several projects focused on giving training and support to patients with genitourinary tumours and relatives.


Several charts are provided below, containing additional information about the financial evolution of the group and a summary of the audit final report of the fiscal year 2022.

2022 Revenue




2022 Turnover per Activity Area

Research	€1,476,792	62.8%	●
Continuing education and training	€840,500	35.7%	●
Activities with patients	€18,700	0.8%	●
Other	€16,647	0.7%	●
Total	€2,352,639		



Area of Continuing Education and Training Projects and other

SOGUG 13th Symposium	€360,100	42.8%	●
2nd Rev Conf of the Euro Congr of Oncology	€9,000	1.1%	●
13th Rev Conf of the Amer Congr of GU	€74,800	8.9%	●
13th Course in Kidney Cancer and GU Tumours	€54,700	6.5%	●
3rd Rev Conf of the Amer Congr of Oncology	€36,900	4.4%	●
11th Course in Prostate and Bladder Cancer	€58,000	6.9%	●
3rd post-ESMO Conference	€30,250	3.6%	●
E-learning	€5,750	0.7%	●
Training Course in Urothelial Cancer	€18,600	2.2%	●
Synergy	€40,000	4.8%	●
Ideas competition	€60,000	7.1%	●
PROFIT	€42,400	5%	●
Others	€50,000	6%	●
Total	€840,500		●





Area of Research and CTs

Prostate cancer	€197,765	13%	●
Kidney cancer	€223,043	15%	●
Bladder cancer	€1,028,202	70%	●
Genitourinary cancer	€27,782	2%	●
Total	€1,476,792		

2022 Expenses

2008-2022 Revenue



2022 Expenses Area of Infrastructure

Public liability insurance	€5,136	1.13%
Banking services and similar	€10,306	2.27%
Financial and legal team	€63,898	14.08%
Own staff	€281,463	62.03%
Expenses of the Board of Directors (trips, meetings of the BoD, work commission expenses)	€7,772	1.71%
Other (rents and fees, supplies, technological services, messaging, other services, etc.)	€85,208	18.78%
Total	€453,782	

2008-2022 Turnover Area of Active Research and CTs

Prostate cancer	€7,576,925	46.7%
Kidney cancer	€4,151,186	25.5%
Bladder cancer	€4,273,865	26.3%
Genitourinary cancer	€243,682	1.5%
Total	€16,245,657	

AND IN 2023...

**25th ANNIVERSARY
ALMOST 600 MEMBERS
THANK YOU SO MUCH**



SOGUG

LIDERANDO LA ONCOLOGÍA
GENITOURINARIA EN ESPAÑA

**THANK YOU ALL FOR MAKING SOGUG
THE LEADING GROUP
IN GENITOURINARY ONCOLOGY IN SPAIN**

#SomosSOGUG #SOGUG25años #multidisciplinarSOGUG

